CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED SOFT-TISSUE AND BONY SARCOMAS - SOUTHWEST ONCOLOGY GROUP-STUDY

Google Scholar
  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (11-1) , 2027-2029
Abstract
Cis-Dichlorodiammineplatinum(II) (DDP), at a dose of 15 mg/m2/per day .times. 5 consecutive days, was administered to 68 evaluable patients with metastatic soft tissue and bony sarcomas. All patients, except 1, had received extensive prior chemotherapy and had progressive disease at the start of the study. Responses observed included 1 complete response in a patient with mesothelioma and 3 partial responses in patients with soft tissue sarcomas (7%). No responses were seen in 18 patients with bony sarcomas. Significant leukopenia and thrombocytopenia were observed in < 20% of evaluable courses, although 2 patients manifested life-threatening leukopenia (< 1000 cells/.mu.l) and 3 had life-threatening thrombocytopenia (< 24,000 cells/.mu.l). Nephrotoxicity was noted in < 25% of evaluable courses. Nausea and/or vomiting was recorded in 55% of evaluable courses. DDP is considered to be marginally active in the secondary treatment of metastatic sarcomas at this dose and schedule. Further studies of DDP in mesothelioma are indicated.